5:32 PM
 | 
Jan 03, 2019
 |  BC Week In Review  |  Clinical News  |  Regulatory

FDA extends PDUFA for Keytruda monotherapy in first-line NSCLC

Merck & Co. Inc. (NYSE:MRK) said FDA has extended by three months the PDUFA date for an sBLA for Keytruda pembrolizumab as monotherapy for first-line treatment of locally...

Read the full 119 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >